Verastem to Present Two-Year Follow-Up Data for Avmapki/Fakzynja Combo in Ovarian Cancer
Summary
Verastem Oncology announced it will present two-year median follow-up data for its Avmapki® Fakzynja® combination therapy in recurrent low-grade serous ovarian cancer at the SGO 2026 Annual Meeting on Women's Cancers. This combination therapy, referred to as AVMAPKI FAKZYNJA CO-PACK, was highlighted in the company's recent 10-K as generating $30.9 million in product revenue for the prior year. For a biotech company, longer-term clinical data for a revenue-generating product is highly material, as it can influence market adoption, prescribing patterns, and future regulatory discussions. Traders will closely monitor the actual data presentation at the SGO 2026 meeting for specific outcomes and their implications for the drug's commercial prospects.
At the time of this announcement, VSTM was trading at $5.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $491M. The 52-week trading range was $4.01 to $11.25. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.